Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.

Plain-language guide to PMID 40962119 (2026): meta-analysis of Semaglutide and Glucagon.

Key Facts

PMID: 40962119
Journal: Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Year: 2026
Study type: Meta-Analysis
Authors: Chen KY et al. (3 authors)
DOI: 10.1016/j.apjo.2025.100245

What This Paper Covers, in Plain Language

What It Covers

Researchers studied Semaglutide and Glucagon in this meta-analysis publication.

To evaluate the association between semaglutide use and the development of NAION.

Why It Was Studied

Semaglutide, a GLP-1 receptor agonist widely prescribed for type 2 diabetes and obesity, has recently been linked to rare ocular adverse events, including non-arteritic anterior ischemic optic neuropathy (NAION).

Given the growing concerns and limited clarity, this systematic review and meta-analysis aims to critically assess the potential association between semaglutide use and NAION risk.

Who the Included Studies Covered

A reviewer screened the potential articles against prespecified eligibility criteria.

The risk of bias in the eligible studies was then evaluated using the Newcastle Ottawa Scale (NOS).

How the Review Was Done

A comprehensive literature search was conducted via different databases from inception to June 3rd, 2025.

Data were then systematically extracted and analyzed.

What Was Measured

Given the growing concerns and limited clarity, this systematic review and meta-analysis aims to critically assess the potential association between semaglutide use and NAION risk.

PubMed files the paper under topics including Optic Neuropathy, Ischemic, Glucagon-Like Peptides, Hypoglycemic Agents, Risk Factors and Diabetes Mellitus, Type 2.

The authors tagged it with the keywords Diabetic retinopathy, NAION, Non-Arteritic Anterior Ischemic Optic Neuropathy, Optic nerve ischemia and Semaglutide.

What This Means in Plain Language

This is a meta-analysis of Semaglutide and Glucagon.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)), a journal based in United States.

More context: the Semaglutide compound page and the Glucagon compound page, all human trials.

Our Notes on the Compounds

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.